Oncternal Therapeutics Inc. (NASDAQ:ONCT) has a beta value of 1.62 and has seen 1,039,960 shares traded in the last trading session. The company, currently valued at $310.5 Million, closed the last trade at $6.29 per share which meant it lost -$0.17 on the day or -2.63% during that session. The ONCT stock price is -50.24% off its 52-week high price of $9.45 and 76.31% above the 52-week low of $1.49. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.44 Million shares traded. The 3-month trading volume is 1.58 Million shares.
The consensus among analysts is that Oncternal Therapeutics Inc. (ONCT) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.1.
Oncternal Therapeutics Inc. (NASDAQ:ONCT) trade information
Despite being -2.63% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Apr 28 when the ONCT stock price touched $6.89-8 or saw a rise of 8.71%. Year-to-date, Oncternal Therapeutics Inc. shares have moved 28.37%, while the 5-day performance has seen it change -0.94%. Over the past 30 days, the shares of Oncternal Therapeutics Inc. (NASDAQ:ONCT) have changed -22.15%. Short interest in the company has seen 527.15 Million shares shorted with days to cover at 333.64.
Wall Street analysts have a consensus price target for the stock at $15.5, which means that the shares’ value could jump 146.42% from current levels. The projected low price target is $9 while the price target rests at a high of $21. In that case, then, we find that the current price level is +233.86% off the targeted high while a plunge would see the stock lose 43.08% from current levels.
Oncternal Therapeutics Inc. (ONCT) estimates and forecasts
4 analysts offering their estimates for the company have set an average revenue estimate of $1.11 Million for the current quarter. 4 have an estimated revenue figure of $1.24 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $578Million and $623Million respectively for this quarter and the next, and analysts expect sales will grow by 92% for the current quarter and 99% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +8.6% over the past 5 years. Earnings growth for 2021 is a modest +74.4%.
Oncternal Therapeutics Inc. (NASDAQ:ONCT)’s Major holders
Insiders own 11.82% of the company shares, while shares held by institutions stand at 21.51% with a share float percentage of 24.39%. Investors are also buoyed by the number of investors in a company, with Oncternal Therapeutics Inc. having a total of 72 institutions that hold shares in the company. The top two institutional holders are Vanguard Group Inc. (The) with over 1.68 Million shares worth more than $8.24 Million. As of December 30, 2020, Vanguard Group Inc. (The) held 3.41% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The other major institutional holder is Ikarian Capital, LLC, with the holding of over 1.03 Million shares as of December 30, 2020. The firm’s total holdings are worth over $5.05 Million and represent 2.09% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Invesco ETF Tr-Invesco DWA Healthcare Momentum ETF. As of December 30, 2020, the former fund manager holds about 2.27% shares in the company for having 1121238 shares of worth $5.49 Million while later fund manager owns 657.89 Thousand shares of worth $5.47 Million as of March 30, 2021, which makes it owner of about 1.33% of company’s outstanding stock.